Literature DB >> 10952565

Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice.

M Ito1, R Nozu, T Kuramochi, N Eguchi, S Suzuki, K Hioki, T Itoh, F Ikeda.   

Abstract

The prophylactic effect of FK463, a new water-soluble echinocandin-like lipopeptide with inhibitory activity against 1, 3-beta-D-glucan synthase, against Pneumocystis carinii infection was investigated with the severe combined immunodeficient (SCID) mouse model. Treatment with FK463, pentamidine, and saline only was performed for 6 weeks from the day after the SCID mice were inoculated intranasally with infected lung homogenates. FK463 at 0.2 or 1.0 mg/kg of body weight, pentamidine at 4 mg/kg, or saline was subcutaneously administered daily into the backs of the SCID mice. The effects of the drugs were evaluated by detection of P. carinii cysts in mouse lung homogenates by toluidine blue O staining, lung histology, and PCR amplification of a P. carinii-specific DNA fragment from the lungs. P. carinii cysts were detected in the lungs of all mice administered saline. In contrast, no cysts were detected in mice administered both doses of FK463 and pentamidine. A specific DNA fragment was amplified from all mice administered saline and at least half or more of the mice administered FK463 and pentamidine. These results indicate that FK463 acts on cyst wall formation but not on trophozoite proliferation and is extremely effective in preventing P. carinii-associated pneumonia. These results suggest that FK463 is potentially useful as a prophylactic agent against P. carinii infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952565      PMCID: PMC90055          DOI: 10.1128/AAC.44.9.2259-2262.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Pneumocystis carinii cysts are susceptible to inactivation by chemical disinfectants.

Authors:  T Kuramochi; K Hioki; M Ito
Journal:  Exp Anim       Date:  1997-07

2.  From the Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus.

Authors: 
Journal:  JAMA       Date:  1989-07-21       Impact factor: 56.272

3.  Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; R D Powell; K Yoneda; M E Rutledge; J E Milder
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

4.  Therapeutic effects of water-soluble echinocandin compounds on Pneumocystis pneumonia in mice.

Authors:  T Furuta; H Muramatsu; A Fujie; S Fujihira; N R Abudullah; S Kojima
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Amplification of mitochondrial ribosomal RNA sequences from Pneumocystis carinii DNA of rat and human origin.

Authors:  A E Wakefield; F J Pixley; S Banerji; K Sinclair; R F Miller; E R Moxon; J M Hopkin
Journal:  Mol Biochem Parasitol       Date:  1990-11       Impact factor: 1.759

6.  WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties.

Authors:  T Iwamoto; A Fujie; K Nitta; S Hashimoto; M Okuhara; M Kohsaka
Journal:  J Antibiot (Tokyo)       Date:  1994-10       Impact factor: 2.649

7.  New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat.

Authors:  D M Schmatz; M A Powles; D McFadden; K Nollstadt; F A Bouffard; J F Dropinski; P Liberator; J Andersen
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

8.  Long-term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine.

Authors:  N Principi; P Marchisio; J Onorato; C Gabiano; L Galli; D Caselli; B Morandi; A Campelli; M Clerici; G C Gattinara
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-06-01

Review 9.  Antibiotics that inhibit fungal cell wall development.

Authors:  M Debono; R S Gordee
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

10.  Effect of sulfamethoxazole-trimethoprim and sulfadoxine-primethamine against fatal pneumocystosis in SCID mice.

Authors:  T Furuta; M Ito; T Kuramochi; K Hioki; T Nomura
Journal:  J Protozool       Date:  1991 Nov-Dec
View more
  9 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients.

Authors:  H A Torres; R F Chemaly; R Storey; E A Aguilera; G M Nogueras; A Safdar; K V I Rolston; I I Raad; D P Kontoyiannis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

Review 3.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

Review 4.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection.

Authors:  Melanie T Cushion; Michael J Linke; Alan Ashbaugh; Tom Sesterhenn; Margaret S Collins; Keeley Lynch; Ronald Brubaker; Peter D Walzer
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

Review 6.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Comparison of echinocandin antifungals.

Authors:  Gregory Eschenauer; Daryl D Depestel; Peggy L Carver
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

9.  Performance of a Real Time PCR for Pneumocystis jirovecii Identification in Induced Sputum of AIDS Patients: Differentiation between Pneumonia and Colonization.

Authors:  Oscar José Chagas; Priscila Paiva Nagatomo; Vera Lucia Pereira-Chioccola; Ricardo Gava; Renata Buccheri; Gilda Maria Barbaro Del Negro; Gil Benard
Journal:  J Fungi (Basel)       Date:  2022-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.